No Data
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Milestone Pharmaceuticals' CARDAMYST: A Game Changer in PSVT Treatment With Significant Market Potential
Individual Investors Account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Ownership, While Institutions Account for 46%
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
TD Cowen analyst Ritu Baral maintains $Milestone Pharmaceuticals(MIST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 45.1%
TD Cowen Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)
Express News | Milestone Pharmaceuticals Inc: 500-Patient Phase 3 Trial (JX02002) Met Its Primary Endpoint
No Data
No Data